Related Experiment Videos
Abstract:
The therapeutic efficacy of the new beta-lactam antibiotic, temocillin, was studied in 30 critically ill patients with peritonitis, abscesses, bronchopneumonia, and serious soft tissue infections. Patients were treated with temocillin Ig intravenously twice daily. The isolated pathogens comprised mainly Escherichia coli and Proteus, but enterococci, Pseudomonas species, Klebsiella pneumoniae, Citrobacter species, Bacteroides species, streptococci and peptococci were also implicated. Temocillin was effective in 21/22 patients with peritonitis, as well as in 6/8 patients with long-lasting infections due to temocillin-sensitive pathogens. No adverse reactions to temocillin were observed. The indications for temocillin in patients undergoing abdominal surgery are discussed.
Insights
Temocillin, a new beta-lactam antibiotic, showed high effectiveness in treating severe infections like peritonitis and abscesses in critically ill patients. This antibiotic was well-tolerated, with no adverse reactions observed during the study.
Area of Science:
- Pharmacology
- Infectious Diseases
- Critical Care Medicine
Background:
- Severe infections pose significant challenges in critically ill patients.
- Beta-lactam antibiotics are crucial for treating bacterial infections.
- Temocillin is a novel beta-lactam antibiotic with potential therapeutic applications.
Purpose of the Study:
- To evaluate the therapeutic efficacy and safety of temocillin in critically ill patients.
- To assess temocillin's effectiveness against a range of bacterial pathogens implicated in serious infections.
Main Methods:
- A study involving 30 critically ill patients with various severe infections.
- Patients received temocillin 1g intravenously twice daily.
- Pathogen identification and sensitivity testing were performed.
Main Results:
- Temocillin demonstrated high efficacy in 21 out of 22 patients with peritonitis.
- Effectiveness was also noted in 6 out of 8 patients with long-lasting infections caused by sensitive pathogens.
- No adverse reactions to temocillin were reported in any patient.
Conclusions:
- Temocillin is an effective and safe therapeutic option for severe bacterial infections in critically ill patients.
- Its efficacy against pathogens like Escherichia coli and Proteus is notable.
- Further consideration of temocillin for patients undergoing abdominal surgery is warranted.